Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2020
A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02632435 (A Pragmatic Randomized Trial Standard of Care Vascular Access Strategies for), which is not on this map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pragmatic Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment OTT 15-06 A Study From the REthinking Clinical Trials Program (REaCT-vascular Access Trastuzumab Study).
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Implantable Ports vs Peripherally Inserted Central Catheters in Breast Cancer Chemotherapy: A Comprehensive Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2025Pooled it
- Peripherally inserted central catheters versus implantable port catheters for cancer patients: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Applicability of TIVAP versus PICC in non-hematological malignancies patients: A meta-analysis and systematic review.PloS one · 2021Pooled it
- A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer.Current oncology (Toronto, Ont.) · 2021Trial
- Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemotherapy in pancreatic cancer.ESMO gastrointestinal oncology · 2026Article
- The Rethinking Clinical Trials (REaCT) Program: A Pragmatic Research Strategy to Improve Cancer Care for Patients, Caregivers, and Healthcare Systems.Current oncology (Toronto, Ont.) · 2025Review
- Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study.Journal of medical Internet research · 2025Article
- Implantable Port Catheters versus Peripherally Inserted Central Catheters for Cancer Patients Requiring Chemotherapy: An RCT-Based Meta-Analysis.Journal of Cancer · 2025Review
- Effect of Two Different Catheter Dressings on Pain, Comfort, and Satisfaction in Chemotherapy Patients: A Randomized Controlled Study.Florence Nightingale journal of nursing · 2024Article
- Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective.Current oncology (Toronto, Ont.) · 2023Article
- Observational
- Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets.JCO clinical cancer informatics · 2023Article
- Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective.Current oncology (Toronto, Ont.) · 2022Review
- The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design.Current oncology (Toronto, Ont.) · 2021Review
- Tailored approach to the choice of long-term vascular access in breast cancer patients.PloS one · 2021Article
- Article
- Risk Factors for Totally Implantable Access Ports Associated Complications in Breast Cancer Patients.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTrastuzumab-based chemotherapy is usually administered through either a peripherally inserted central catheter (PICC) or a totally implanted vascular access device (PORT). As the most effective type of access is unknown, a feasibility trial, prior to conducting a large pragmatic trial, was undertaken.
methodsThe trial methodology utilized the integrated consent model incorporating oral consent. Patients receiving trastuzumab-based neo/adjuvant chemotherapy for early-stage breast cancer were randomized to a PICC or PORT insertion. Feasibility was reflected through a combination of endpoints; however, the a priori definition of feasibility was > 25% of patients approached agreed to randomization and > 25% of physicians approached patients. Secondary outcomes included rates of line-associated complications such as thrombotic events requiring anticoagulation, line infections or phlebitis.
resultsDuring the study period, 4/15 (26.7%) medical oncologists approached patients about study participation. Of 59 patients approached, 56 (94.9%) agreed to randomization, 29 (51.8%) were randomized to PICC and 27 (48.2%) to PORT access. Overall, 17.2% (5/29) and 14.8% (4/27) of patients had at least one line-associated complication in the PICC and PORT arms respectively. The study was terminated early due to slow accrual.
conclusionThe study met its feasibility endpoints with respect to patient and physician engagement. However, the slow rate of accrual (56 patients in 2 years) means that conducting a large pragmatic trial would require additional strategies to make such a study possible.
trial registrationClinicalTrials.gov Identifier: NCT02632435.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.